DavidMWaterhouseMD

Oncology • Cincinnati, OH

Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Waterhouse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Waterhouse's full profile

Already have an account?

Office
3301 Mercy Health Blvd
Ste 100
Cincinnati, OH 45211
Phone+1 513-751-2145

Fax+1 513-751-1848

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 1989 - 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1985 - 1988
University of Massachusetts Medical SchoolClass of 1985

Certifications & Licensure

OH State Medical License 1993 - 2025
MA State Medical License 1986 - 2024
KY State Medical License 1997 - 2018
MI State Medical License 1989 - 1996
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Completed
Phase 2
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
Recruiting
Phase 2
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Start of enrollment: 2020 Mar 11
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving S...
Ihtisham Sultan, David M Waterhouse, Divyan Chopra, Alexander Lonshteyn, Derek Weycker
Advances in Therapy. 2024-12-01
1 citations
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
David M Waterhouse, Sacha Rothschild, Christophe Dooms, Bertrand Mennecier, Farastuk Bozorgmehr
Lung Cancer. 2024-10-01
Sotorasib versus docetaxel: evidence supporting CodeBreaK 200.
Luis Paz-Ares, Bhakti Mehta, Yang Wang, David Waterhouse, Adrianus Johannes de Langen
The Lancet. Oncology. 2024-08-01

Press Mentions

OHC's Waterhouse Feels Privileged to Share in Oncology Patients’ Highs and LowsFebruary 26th, 2021
Oncology Care Model Supports Practice & Benefits Medicare's Bottom LineOctober 23rd, 2019
Increasing Biomarker Testing Rates for Patients with NSCLCDecember 9th, 2023